Due to the volume of traffic and need to expand we have now moved the popular CambridgeBiomed blog to its own domain. All the posts have been transferred and we look forward to continuing to publish topical posts on the life sciences market.
We will keep the previous site CambridgeBiomed.Wordpress.com up for the transition period but it will not be updated, all content will be at this site.
If you have any suggestions for content please be sure to let us know !
Bob
Every week in England and Wales three babies are born with spina bifida and 13 pregnancies are terminated when a neural tube defect is discovered. Around two thirds of these events could be avoided by adding folic acid to flour
High blood sugar readings have been tied to a greater risk for heart disease. While these blood sugar readings may signal risk of pre-diabetes or diabetes, they may not be a sign that heart disease waits ahead.
Cambridge Biomedical’s experience with bioanalytical assay development, optimization, validation and diagnostic testing has proved instrumental in assisting biotechnology and pharmaceutical companies that are focusing on therapies for orphan and ultra-rare disease in expediting their development programs.
Dr. John Reddington, COO of Cambridge Biomedical, commented that, “Our track record and experience with the needs of the orphan and ultra-rare disease drug development market, combined with our scientific expertise and wide range of technology platforms, has proven essential in reducing the time to market for this critical sector of the market. Throughout our organization we never forget that our primary mission is to support the ultimate end-user: the patient.”
Cambridge Biomedical
Since 1997, Cambridge Biomedical has partnered with our clients by providing a diverse range of services from pre-clinical to post market. Including; assay development, optimization, validation and diagnostic testing. Conveniently located to support the Northeast pharmaceutical development market, yet with a national and global reach. Our personalized project management, approach along with a focus on delivering quality results and regulatory submission ready documentation and rapid turnaround times, ensure we meet our client’s product development timelines.
The first 3D printed skull transplant has taken place in the Netherlands — and they’ve released some of the early footage of the successful surgery.
The surgery was performed in the University Medical Center at Utrecht University, after surgeons there began treating a patient with a condition that was causing a thickening of the skull to almost 3 times its normal thickness, putting pressure on the brain.